A practical guide to folic acid, folinic acid, L-methylfolate, MTHFR, homocysteine, Deplin, and why the differences actually matter in psychiatric practice.
Here is a scene that may happen to you in the near future:
One client says, "I found out I have the MTHFR mutation, so I should take folic acid, right?"
Another client is "taking folate" but is not even sure which kind.
A third was told that folate "helps" with autism.
A fourth asks about "Deplin".
Here is the problem. We use the word folate as if all of these are the same thing.
They are not.
Now let's build this from the ground up.
Folate Is a Family, Not One Molecule
"Folate" is really a family name. It stands for vitamin B9. But B9 comes in several forms (Scaglione & Panzavolta, Xenobiotica, 2014).
Folate is the umbrella term for vitamin B9 compounds.
Folic acid is the synthetic form used in vitamins and fortified foods.
Folinic acid is a reduced folate, also called leucovorin.
L-methylfolate is 5-MTHF, the methylated form of folate. This is what Deplin contains.
Same vitamin family. Different chemical forms. Different spots in the folate pathway.
The Folate Pathway
Think of folate as raw material that the body keeps converting into forms it can use for different jobs.
Here is the part of the pathway that matters most:
Folic acid — the synthetic form found in supplements and fortified foods
↓ must be converted into reduced forms
Reduced folate pool — folinic acid (leucovorin) can enter around here
↓
5,10-methylene-THF
↓ MTHFR works here
5-MTHF (L-methylfolate)
↓ works with vitamin B12
Homocysteine → Methionine
↓
SAM (S-adenosylmethionine) — one of the body's major methyl donors
↓
Methylation — used in thousands of biochemical reactions throughout the body, including the brain.
☕️ The shortcut to remember
Folic acid starts upstream. It has to travel through several metabolic steps before contributing to the 5-MTHF pool.
Folinic acid enters farther downstream. It is already a reduced folate, so it bypasses some of the early processing required by folic acid.
L-methylfolate enters at 5-MTHF. It is already the form produced by the MTHFR-dependent step, which is why MTHFR comes up so often in psychiatric discussions of folate.
Methylation is the process of adding a small chemical tag called a methyl group to another molecule. Think of that tag as an instruction that can change what a molecule does, how it is processed, or whether certain cellular processes are turned up or down.
And this is where the pathway becomes relevant to psychiatry. Folate metabolism contributes to the production of SAM, which participates in methylation reactions throughout the nervous system.
But be careful with the popular internet version of this story: "more methylation = more neurotransmitters = better mood." Biology is not that simple. Folate metabolism intersects with neurotransmitter biology, but adding more folate does not automatically produce more serotonin or a better antidepressant response.
MTHFR: The Famous Enzyme Almost Nobody Understands
MTHFR stands for methylenetetrahydrofolate reductase. That is a mouthful, but its main job here is easy: it turns 5,10-methylene-THF into 5-MTHF.
Now the key point that gets missed constantly:
A common MTHFR gene variant is not the same as MTHFR deficiency disease.
True MTHFR deficiency is a rare, serious inherited disease.
Common MTHFR variants are ordinary genetic differences that huge numbers of healthy people carry.
The two variants you will hear about are C677T and A1298C. You can carry one copy (heterozygous) or two copies (homozygous). These variants are very common. A large share of the general population carries at least one. Carrying one does not mean you are sick.
Do these variants matter? Meta-analytic data link the C677T variant to a modestly higher risk of bipolar disorder and schizophrenia (Meng et al., PLoS One, 2022), and additional meta-analyses have associated C677T with a small increase in risk of unipolar depression (Gilbody et al., American Journal of Epidemiology, 2007; Peerbooms et al., Brain, Behavior, and Immunity, 2011; Zhang et al., Frontiers in Psychiatry, 2022). But "a slightly higher risk across a large group" is very different from "this totally explains your illness".
Ask the useful question: Does knowing a patient has an MTHFR variant actually change what we do? Often, it does not. This is exactly where a lot of expensive, direct-to-consumer genetic testing gets oversold.
☕️ Homocysteine: The Lab That Makes the Pathway Click
Homocysteine is one of the best ways to see this pathway in action.
Here is the link: 5-MTHF plus vitamin B12 help turn homocysteine back into methionine. If that step is not working well, homocysteine builds up in the blood.
So a high homocysteine level can be a clue that something in folate or B12 metabolism is off. But it is not a test for MTHFR, and it is not caused by one thing.
Homocysteine can rise from many causes, including:
Low B12
Low folate
Low vitamin B6
Poor kidney function
Low thyroid function
Certain medications
Older age and lifestyle factors
A useful way to hold this: a gene variant tells you what might happen. A lab like homocysteine can tell you more about what is actually happening right now but it still has to be read in context.
You Can't Talk About Folate Without Talking About Vitamin B12
Folate and vitamin B12 are partners. They work together at the same step, using an enzyme called methionine synthase to convert homocysteine into methionine.
This partnership creates a real trap. If someone is low on B12, folate can get "stuck" in its methyl form and cannot be recycled properly.
There is another important clinical issue: giving folate can correct the megaloblastic anemia caused by B12 deficiency without correcting the underlying B12-dependent neurologic problem. In other words, the blood count can look better while neurologic injury from untreated B12 deficiency continues.
The clinical takeaway is simple: before assuming a psychiatric patient just needs more folate, think about B12 first.
Labs that may help would include a CBC, B12, folate, methylmalonic acid (MMA), and homocysteine. Most will order them because they will potentially change the plan, not just because.
So Where Does Deplin Fit?
Deplin is L-methylfolate (5-MTHF). Its whole selling point is that it is the already-activated form, so it skips the MTHFR step. That is the biochemical logic.
But biochemical logic and real proof are two different things, so let's separate them:
What Deplin is: L-methylfolate sold as a "medical food," not a standard FDA-approved drug.
How it has been studied in depression: as an add-on to antidepressants — not as a stand-alone treatment — usually at 15 mg per day.
What the trials show: Papakostas et al. (American Journal of Psychiatry, 2012) reported two sequential randomized trials. The first trial was negative — L-methylfolate did not separate from placebo. The second trial, which used 15 mg per day throughout, did show a significant benefit over placebo when added to an SSRI in patients whose depression had not fully responded (number needed to treat of roughly 6 for response).
What the bigger picture shows: A later systematic review and meta-analysis found the overall benefit is real but modest (Maruf et al., Pharmacopsychiatry, 2022).
Who may benefit most: Some data point to patients with obesity or inflammation, though this is still being sorted out.
Should we reach for L-methylfolate because someone has an MTHFR variant, or because they have hard-to-treat depression?
☕️ ☕️ The evidence supports thinking of it as an add-on choice for stubborn depression, not as a "fix" for a common gene result.
Then What Is Leucovorin and Why Is It in the News?
Leucovorin is folinic acid. It is another reduced folate, but it is not methylfolate.
Same family, different form.
Leucovorin has long-established uses in medicine, such as "rescuing" healthy cells after high-dose methotrexate and supporting certain chemotherapy regimens.
More recently, leucovorin has entered a very different conversation: the brain and folate transport.
That leads to the next idea.
Cerebral Folate Deficiency Is a Different Problem
Here it helps to separate three ideas that often get blended together:
Folate deficiency: Not enough folate in the body.
Impaired folate metabolism: The body has folate but cannot process it normally. This is where the MTHFR conversation often enters.
Impaired folate transport into the brain: Folate may be normal in the blood, but insufficient folate reaches the cerebrospinal fluid and brain.
And this is where the whole folate conversation takes a turn: the problem isn't always how the body processes folate. Sometimes the problem is getting folate into the brain.
In cerebral folate deficiency, blood folate can look normal while folate in the cerebrospinal fluid (CSF) is low.
This matters because disorders of cerebral folate transport can cause serious neurologic problems in children, including developmental delay, movement abnormalities, and difficult-to-control seizures — and can include autistic features. In specific folate-transport disorders, leucovorin (folinic acid) may be used to increase folate availability to the central nervous system (Goldman & Chabner, New England Journal of Medicine, 2026).
You may have seen headlines linking leucovorin to autism. Handle these carefully. A specific, diagnosable disorder involving folate transport is very different from autism in general. The science here is still developing, and headlines might run ahead of the evidence.
An important note: Folic acid still has the strongest proof for preventing neural tube defects in pregnancy.
What Should a PMHNP Actually Do With This?
A simple workflow keeps you out of trouble when a patient brings up folate, MTHFR, or methylfolate:
Ask why it was tested. Depression? Nutrition? High homocysteine? A direct-to-consumer gene report? A neurologic disease?
Check the context. Diet, medications, and any absorption problems.
Consider the right labs — B12 (with MMA if needed), folate, and homocysteine (but only when they might change your plan).
Do not treat a common gene variant like a disease. An MTHFR variant alone rarely changes management.
If you are considering L-methylfolate for depression, treat it as an add-on decision for stubborn symptoms, not as a way to "fix" a gene result.
Remember leucovorin is not just another brand of methylfolate. It is folinic acid, with its own uses.
Eva's Take
Folate is confusing because we have crammed several different molecules, gene variants, lab results, and diseases into one tired little word: folate.
So here is the whole article in one line:
You don't need to memorize the pathway. You need to know where the patient's problem is happening in it.
Is the problem not enough folate?
Is it how folate is being processed?
Is a cofactor such as B12 interfering with the pathway?
Or is the problem transporting folate into the brain?
Get that, and folic acid, folinic acid, MTHFR, L-methylfolate, B12, homocysteine, Deplin, and leucovorin make a lot more sense.
Selected References
Gilbody, S., Lewis, S., & Lightfoot, T. (2007). Methylenetetrahydrofolate reductase (MTHFR) genetic polymorphisms and psychiatric disorders: A HuGE review. American Journal of Epidemiology, 165(1), 1–13.
Goldman, I. D., & Chabner, B. A. (2026). Cerebral folate deficiency, autism, and the role of leucovorin. New England Journal of Medicine.
Maruf, A. A., Poweleit, E. A., Brown, L. C., Strawn, J. R., & Bousman, C. A. (2022). Systematic review and meta-analysis of L-methylfolate augmentation in depressive disorders. Pharmacopsychiatry, 55(3), 139–147.
Meng, X., Zheng, J. L., Sun, M. L., Lai, H. Y., Wang, B. J., Yao, J., & Wang, H. (2022). Association between MTHFR (677C>T and 1298A>C) polymorphisms and psychiatric disorder: A meta-analysis. PLoS One, 17(7), e0271170.
Papakostas, G. I., Shelton, R. C., Zajecka, J. M., Etemad, B., Rickels, K., Clain, A., Baer, L., Dalton, E. D., Sacco, G. R., Schoenfeld, D., Pencina, M., Meisner, A., Bottiglieri, T., Nelson, E., Mischoulon, D., Alpert, J. E., Barbee, J. G., Zisook, S., & Fava, M. (2012). L-methylfolate as adjunctive therapy for SSRI-resistant major depression: Results of two randomized, double-blind, parallel-sequential trials. American Journal of Psychiatry, 169(12), 1267–1274.
Peerbooms, O. L., van Os, J., Drukker, M., et al. (2011). Meta-analysis of MTHFR gene variants in schizophrenia, bipolar disorder and unipolar depressive disorder: Evidence for a common genetic vulnerability? Brain, Behavior, and Immunity, 25(8), 1530–1543.
Scaglione, F., & Panzavolta, G. (2014). Folate, folic acid and 5-methyltetrahydrofolate are not the same thing. Xenobiotica, 44(5), 480–488.
Zhang, Y. X., Yang, L. P., Gai, C., et al. (2022). Association between variants of MTHFR genes and psychiatric disorders: A meta-analysis. Frontiers in Psychiatry, 13, 976428.